Clinical trials
Neoplasms trials in Italy with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
55 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2006 | 2 |
| 2007 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 6 |
| 2019 | 7 |
| 2020 | 7 |
| 2021 | 9 |
| 2022 | 4 |
| 2023 | 2 |
| 2024 | 5 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 55 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 7 |
| National Cancer Institute, Naples | 4 |
| European Institute of Oncology | 3 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 3 |
| Antea Foundation | 2 |
| Azienda Ospedaliera Universitaria Integrata Verona | 2 |
| Fondazione ANT Franco Pannuti ETS | 2 |
| Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2 |
| Ospedale Andrea Tortora di Pagani | 2 |
| University of Milano Bicocca | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 55 |
| Lung Neoplasms | 5 |
| Breast Neoplasms | 4 |
| Neoplasm Metastasis | 4 |
| Pain | 4 |
| COVID-19 | 3 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Melanoma | 3 |
| Anxiety Disorders | 2 |
| Brain Neoplasms | 2 |
Trials
Showing 1 to 25 of 55. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.